This company is no longer active
Diffusion Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Diffusion Pharmaceuticals's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 23.9% annually.
Información clave
-2.2%
Tasa de crecimiento de los beneficios
72.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -91.9% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Jun 2023 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02
Aug 12We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully
Feb 25
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth
Nov 12We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate
Jun 25Diffusion Pharmaceuticals EPS misses by $0.02
May 10We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation
Nov 23Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Diffusion Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -13 | 10 | 4 |
| 31 Mar 23 | 0 | -15 | 10 | 6 |
| 31 Dec 22 | 0 | -16 | 9 | 7 |
| 30 Sep 22 | 0 | -15 | 8 | 7 |
| 30 Jun 22 | 0 | -24 | 8 | 8 |
| 31 Mar 22 | 0 | -24 | 8 | 8 |
| 31 Dec 21 | 0 | -24 | 7 | 8 |
| 30 Sep 21 | 0 | -25 | 7 | 10 |
| 30 Jun 21 | 0 | -17 | 7 | 11 |
| 31 Mar 21 | 0 | -18 | 7 | 11 |
| 31 Dec 20 | 0 | -16 | 6 | 9 |
| 30 Sep 20 | 0 | -16 | 6 | 9 |
| 30 Jun 20 | 0 | -14 | 5 | 7 |
| 31 Mar 20 | 0 | -12 | 5 | 6 |
| 31 Dec 19 | 0 | -12 | 5 | 7 |
| 30 Sep 19 | 0 | -14 | 5 | 6 |
| 30 Jun 19 | 0 | -18 | 5 | 6 |
| 31 Mar 19 | 0 | -18 | 6 | 6 |
| 31 Dec 18 | 0 | -27 | 6 | 6 |
| 30 Sep 18 | 0 | -20 | 6 | 6 |
| 30 Jun 18 | 0 | -10 | 6 | 6 |
| 31 Mar 18 | 0 | 4 | 6 | 6 |
| 31 Dec 17 | 0 | -3 | 6 | 5 |
| 30 Sep 17 | 0 | -7 | 6 | 5 |
| 30 Jun 17 | 0 | -15 | 8 | 5 |
| 31 Mar 17 | 0 | -30 | 6 | 5 |
| 31 Dec 16 | 0 | -18 | 9 | 6 |
| 30 Sep 16 | 0 | -18 | 9 | 6 |
| 30 Jun 16 | 0 | -14 | 5 | 6 |
| 31 Mar 16 | 0 | -12 | 6 | 5 |
| 31 Dec 15 | 0 | -7 | 3 | 4 |
Ingresos de calidad: DFFN is currently unprofitable.
Margen de beneficios creciente: DFFN is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DFFN is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Acelerando crecimiento: Unable to compare DFFN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: DFFN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Rentabilidad financiera
Alta ROE: DFFN has a negative Return on Equity (-91.92%), as it is currently unprofitable.